+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Scar - Pipeline Review, H1 2017

  • ID: 4115114
  • Report
  • March 2017
  • 89 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Altacor Ltd
  • BirchBioMed Inc
  • Clanotech AB
  • FirstString Research Inc
  • Moerae Matrix Inc
  • MORE
Scar - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H1 2017, provides an overview of the Scar (Dermatology) pipeline landscape.

A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Altacor Ltd
  • BirchBioMed Inc
  • Clanotech AB
  • FirstString Research Inc
  • Moerae Matrix Inc
  • MORE
Introduction

Scar - Overview

Scar - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Scar - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Scar - Companies Involved in Therapeutics Development

3M Drug Delivery Systems

Albireo Pharma Inc

Altacor Ltd

Beech Tree Labs Inc

BirchBioMed Inc

BLR Bio LLC

Clanotech AB

Escape Therapeutics Inc

FirstString Research Inc

Kringle Pharma Inc

Moerae Matrix Inc

Pharmaxis Ltd

Promore Pharma

RXi Pharmaceuticals Corp

Synedgen Inc

VBS Pharmaceuticals

Scar - Drug Profiles

A-3914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-5425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLR-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BTL-slo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLT-28643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FibroStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granexin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICX-RHY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MMI-0100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Fibrotic Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nefopam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharide for Wounds and Scars - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXL-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-34240 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lysyl Oxidase for Scar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tranilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Scar - Dormant Projects

Scar - Discontinued Products

Scar - Product Development Milestones

Featured News & Press Releases

Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug

Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream

Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model

Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference

Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109

Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications

Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference

Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics

Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting

Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO

Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference

Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology

Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Scar, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Scar - Pipeline by 3M Drug Delivery Systems, H1

Scar - Pipeline by Albireo Pharma Inc, H1

Scar - Pipeline by Altacor Ltd, H1

Scar - Pipeline by Beech Tree Labs Inc, H1

Scar - Pipeline by BirchBioMed Inc, H1

Scar - Pipeline by BLR Bio LLC, H1

Scar - Pipeline by Clanotech AB, H1

Scar - Pipeline by Escape Therapeutics Inc, H1

Scar - Pipeline by FirstString Research Inc, H1

Scar - Pipeline by Kringle Pharma Inc, H1

Scar - Pipeline by Moerae Matrix Inc, H1

Scar - Pipeline by Pharmaxis Ltd, H1

Scar - Pipeline by Promore Pharma, H1

Scar - Pipeline by RXi Pharmaceuticals Corp, H1

Scar - Pipeline by Synedgen Inc, H1

Scar - Pipeline by VBS Pharmaceuticals, H1

Scar - Dormant Projects, H1

Scar - Discontinued Products, H1

List of Figures:

Number of Products under Development for Scar, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
4 of 5
  • 3M Drug Delivery Systems
  • Albireo Pharma Inc
  • Altacor Ltd
  • Beech Tree Labs Inc
  • BirchBioMed Inc
  • BLR Bio LLC
  • Clanotech AB
  • Escape Therapeutics Inc
  • FirstString Research Inc
  • Kringle Pharma Inc
  • Moerae Matrix Inc
  • Pharmaxis Ltd
  • Promore Pharma
  • RXi Pharmaceuticals Corp
  • Synedgen Inc
  • VBS Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll